The association between the polymorphisms of TNF-α and non-Hodgkin lymphoma: a meta-analysis

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12509-12517

  He, Yong Qiao ^a   Zhu, Jin Hong ^b   Huang, Shao Yi ^a   Cui, Zhuo ^c   He, Jing ^a   Jia, Wei Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Meta analysis; NHL; Polymorphism; TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; META ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHOMA, NON-HODGKIN; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923136167     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2569-6     Document Type: Article

References (70)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Fears SSDaT (1992) Non-Hodgkin’s lymphoma time trends: United States and international data.
3. Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, et al. The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer. 1999;35:627–33.
4. K. N. Naresh VSCSS (2000) Distribution of various subtypes of non-Hodgkin’s lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO classifications.
5. Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011;21:293–8.
6. Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:405–8.
7. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551–9.
8. van Leeuwen MT, Grulich AE, Webster AC, McCredie MR, Stewart JH, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood. 2009;114:630–7.
9. Balkwill F (2002) Tumor necrosis factor or tumor promoting factor?
10. Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, et al. Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents. 1992;6:103–7.
11. Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol. 1997;15:499–508.
12. Warzocha K, Salles G, Bienvenu J, Barbier Y, Bastion Y, et al. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas. Leukemia. 1997;11 Suppl 3:441–3.
13. Li D, Li G, Wang B. Serum tumor necrosis factor-alpha levels in non-Hodgkin’s lymphoma patients and its relationship to prognosis. Zhonghua Zhong Liu Za Zhi. 1997;19:293–6.
14. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcome. Blood. 1998;91:3574–81.
15. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195–9.
16. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens. 1998;51:605–12.
17. Demeter J, Porzsolt F, Ramisch S, Schmid M, Messer G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in hairy cell leukaemia. Br J Haematol. 1997;97:132–4.
18. Chouchane L, Ahmed SB, Baccouche S, Remadi S. Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer. 1997;80:1489–96.
19. Demeter J, Porzsolt F, Ramisch S, Schmidt D, Schmid M, et al. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol. 1997;97:107–12.
20. Fitzgibbon J, Grenzelias D, Matthews J, Lister TA, Gupta RK. Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol. 1999;107:388–91.
21. Wihlborg C, Sjoberg J, Intaglietta M, Axdorph U, Pisa EK, et al. Tumour necrosis factor-alpha cytokine promoter gene polymorphism in Hodgkin’s disease and chronic lymphocytic leukaemia. Br J Haematol. 1999;104:346–9.
22. Tsukasaki K, Miller CW, Kubota T, Takeuchi S, Fujimoto T, et al. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res. 2001;61:3770–4.
23. Bogunia-Kubik K, Mazur G, Urbanowicz I, Wrobel T, Kuliczkowski K, et al. Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia. Int J Immunogenet. 2005;33:21–4.
24. Hellmig S, Fischbach W, Goebeler-Kolve ME, Folsch UR, Hampe J, et al. A functional promotor polymorphism of TNF-alpha is associated with primary gastric B-Cell lymphoma. Am J Gastroenterol. 2005;100:2644–9.
25. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 2006;107:4101–8.
26. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 2006;66:9771–80.
27. Bel Hadj Jrad B, Chatti A, Laatiri A, Ahmed SB, Romdhane A, et al. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin’s lymphomas. Eur J Haematol. 2007;78:117–22.
28. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin lymphoma study. Carcinogenesis. 2007;28:704–12.
29. Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, et al. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev. 2008;17:3161–9.
30. Jevtovic-Stoimenov T, Kocic G, Pavlovic D, Macukanovic-Golubovic L, Marjanovic G, et al. Polymorphisms of tumor-necrosis factor-alpha −308 and lymphotoxin-alpha + 250: possible modulation of susceptibility to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mononuclear cells. Leuk Lymphoma. 2008;49:2163–9.
31. Aissani B, Ogwaro KM, Shrestha S, Tang J, Breen EC, et al. The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin’s lymphoma. J Acquir Immune Defic Syndr. 2009;52:170–9.
32. Andrie E, Michos A, Kalampoki V, Pourtsidis A, Moschovi M, et al. Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol. 2009;83:334–42.
33. Fernberg P, Chang ET, Duvefelt K, Hjalgrim H, Eloranta S, et al. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control. 2010;21:759–69.
34. Thunberg U, Enblad G, Turesson I, Berglund M. Genetic variation in tumor necrosis factor and risk of diffuse large B-cell lymphoma and follicular lymphoma: differences between subgroups in Swedish patients. Leuk Lymphoma. 2010;51:1563–6.
35. Xiao H, Zhang K. Genetic polymorphisms of tumor necrosis factor-alpha and lymphotoxin-alpha in Chinese patients with non-Hodgkin lymphoma. Ann Hematol. 2010;90:725–7.
36. Ibrahim A, Abdel Rahman H, Khorshied M, Sami R, Nasr N, et al. Tumor necrosis factor alpha−308 and lymphotoxin alpha + 252 genetic polymorphisms and the susceptibility to non-Hodgkin lymphoma in Egypt. Leuk Res. 2011;36:694–8.
37. Bi X, Zheng T, Lan Q, Xu Z, Chen Y, et al. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma. Am J Hematol. 2012;87:766–9.
38. Hosgood 3rd HD, Au WY, Kim HN, Liu J, Hu W, et al. IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations. Int J Hematol. 2013;97:793–9.
39. Lech-Maranda E, Mlynarski W, Grzybowska-Izydorczyk O, Borowiec M, Pastorczak A, et al. Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosom Cancer. 2013;52:287–96.
40. Liu J, Song B, Wang T, Liu Y, Hao J, et al. Genetic variations in CTLA-4, TNF-alpha, and LTA and susceptibility to T-cell lymphoma in a Chinese population. Cancer Epidemiol. 2013;37:930–4.
41. Nasiri H, Farajnia S, Rezamand A, Movassaghpour AA, Esmaeili HA, et al. Genetic variations of tumor necrosis factor -alpha−308 and lymphotoxin-alpha + 252 in Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia Patients. Iran J Basic Med Sci. 2013;16:990–5.
42. Yri OE, Ekstrom PO, Hilden V, Gaudernack G, Liestol K, et al. Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Leuk Lymphoma. 2013;54:2205–14.
43. Swartz MK. The PRISMA statement: a guideline for systematic reviews and meta-analyses. J Pediatr Health Care. 2011;25:1–2.
44. Wang SS, Cozen W, Cerhan JR, Colt JS, Morton LM, et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res. 2007;67:5042–54.
45. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood. 2008;112:5150–60.
46. Abdou AM, Gao X, Cozen W, Cerhan JR, Rothman N, et al. Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma. Leukemia. 2010;24:1055–8.
47. Chen Y, Zheng T, Lan Q, Foss F, Kim C, et al. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood. 2011;117:585–90.
48. Mainou-Fowler T, Dickinson AM, Taylor PR, Mounter P, Jack F, et al. Tumour necrosis factor gene polymorphisms in lymphoproliferative disease. Leuk Lymphoma. 2000;38:547–52.
49. Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, et al. Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol. 2006;133:293–300.
50. Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood. 2008;112:2694–702.
51. McAulay KA, Haque T, Crawford DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer. 2009;101:1019–27.
52. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27–38.
53. Au WY, Fung A, Wong KF, Chan CH, Liang R. Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population. Leuk Lymphoma. 2006;47:2189–93.
54. Babel N, Vergopoulos A, Trappe RU, Oertel S, Hammer MH, et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation. 2007;84:387–91.
55. Takashiba S, Shapira L, Amar S, Van Dyke TE. Cloning and characterization of human TNFα promoter region. Gene. 1993;131:307–8.
56. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25:409–16.
57. Ding B, Fu S, Wang M, Yue C, Wang W, et al. Tumor necrosis factor alpha −308 G>A polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2012;22:213–9.
58. Zhang HL, Zhang YJ. A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer. Tumour Biol. 2013;34:1659–65.
59. Hong Y, Ge Z, Jing C, Shi J, Dong X, et al. Functional promoter −308G>A variant in tumor necrosis factor alpha gene is associated with risk and progression of gastric cancer in a Chinese population. PLoS ONE. 2013;8:e50856.
60. Fang F, Yao L, Yu XJ, Yu L, Wu Q. TNFalpha −308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls. Breast Cancer Res Treat. 2010;122:267–71.
61. Xie L, Liang XN, Deng Y, Qin X, Li S. TNF-alpha-308G/A polymorphisms and nasopharyngeal cancer risk: a meta-analysis. Eur Arch Otorhinolaryngol. 2013;270:1667–72.
62. Azmy IA, Balasubramanian SP, Wilson AG, Stephenson TJ, Cox A, et al. Role of tumour necrosis factor gene polymorphisms (−308 and −238) in breast cancer susceptibility and severity. Breast Cancer Res. 2004;6:R395–400.
63. Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer. 2008;98:1443–51.
64. Zhou P, Lv GQ, Wang JZ, Li CW, Du LF, et al. The TNF-alpha-238 polymorphism and cancer risk: a meta-analysis. PLoS ONE. 2011;6:e22092.
65. Yu JY, Li L, Ma H, Liu K, Cheng X, et al. Tumor necrosis factor-alpha 238 G/A polymorphism and gastric cancer risk: a meta-analysis. Tumour Biol. 2013;34:3859–63.
66. Cheng K, Zhao YJ, Liu L, Wan JJ. Tumor necrosis factor-alpha 238 G/A polymorphism and risk of hepatocellular carcinoma: evidence from a meta-analysis. Asian Pac J Cancer Prev. 2013;14:3275–9.
67. Cen G, Wu W. Association between tumor necrosis factor-alpha 857C/T polymorphism and gastric cancer: a meta-analysis. Tumour Biol. 2013;34:3383–8.
68. Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010;42:661–4.
69. Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. 2011;7:e1001378.
70. Tan DE, Foo JN, Bei JX, Chang J, Peng R, et al. Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet. 2013;45:804–7.